Simplify Logo

Full-Time

Manager/Sr. Manager

Digital Marketing

Posted on 7/15/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$135k - $195kAnnually

+ Performance Bonus + Equity + Health Benefits

Senior, Expert

San Francisco, CA, USA

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Marketing
Data Analysis
Requirements
  • 6+ years of digital experience within Pharma
  • 4+ years overseeing owned channel development
  • Successful launch experience in a competitive market
  • Extensive knowledge of pharmaceutical marketing regulations
  • Proven track record of designing and implementing successful user-driven, data-based, digital marketing strategies
  • Excellent oral, written, and presentation skills
  • High level of comfort with, and ability to communicate about marketing platforms and site development
Responsibilities
  • Team member responsible for crafting and executing owned channel strategies related to Acoramidis and ATTR-CM (ex. Email, SMS, websites)
  • Craft detailed audience-based journeys that account for all owned messaging touchpoints and likely paid media touchpoints
  • Own development, launch and measurement planning across owned
  • Translate concepts into compelling strategic narratives for executive presentations and review
  • Manage agency relationship(s) for all email and website work including external developers and software vendors
  • Manage internal processes related to owned channel development and oversight with cross-functional stakeholders including legal and IT
  • Partner with legal and IT to standardize opt-in and user data management practices across BridgeBio
  • Manage budget and scope(s) related to owned channel work
  • Stay current on industry issues that directly and indirectly affect these workstreams and the broader digital work
  • Assess and put forward vendors that you believe will positively impact business objectives and product goals
  • Design marketing tests, present findings and recommendations, oversee optimizations
  • Set campaign goals and KPIs alongside agency partners and analytics team
  • Review reporting, understand data-based insights, and optimize campaign executions accordingly

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

53%

2 year growth

56%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.
INACTIVE